| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatectomy | 54 | 2020 | 477 | 4.780 |
Why?
|
| Robotics | 44 | 2015 | 269 | 4.440 |
Why?
|
| Prostatic Neoplasms | 55 | 2021 | 1769 | 3.090 |
Why?
|
| Laparoscopy | 35 | 2020 | 773 | 2.750 |
Why?
|
| Erectile Dysfunction | 8 | 2010 | 75 | 0.780 |
Why?
|
| Urology | 4 | 2020 | 117 | 0.730 |
Why?
|
| Prostate | 10 | 2015 | 393 | 0.710 |
Why?
|
| Robotic Surgical Procedures | 4 | 2020 | 306 | 0.610 |
Why?
|
| Lymph Node Excision | 3 | 2015 | 220 | 0.590 |
Why?
|
| Urinary Incontinence | 6 | 2012 | 213 | 0.560 |
Why?
|
| Postoperative Hemorrhage | 2 | 2015 | 46 | 0.560 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2015 | 98 | 0.540 |
Why?
|
| Middle Aged | 57 | 2020 | 25974 | 0.510 |
Why?
|
| Head-Down Tilt | 1 | 2015 | 5 | 0.510 |
Why?
|
| Adenocarcinoma | 7 | 2021 | 1194 | 0.510 |
Why?
|
| Male | 77 | 2021 | 42411 | 0.500 |
Why?
|
| Ear Diseases | 1 | 2015 | 20 | 0.500 |
Why?
|
| Urinary Bladder, Neurogenic | 3 | 2011 | 25 | 0.500 |
Why?
|
| Clinical Clerkship | 2 | 2007 | 118 | 0.490 |
Why?
|
| Blood Loss, Surgical | 1 | 2015 | 115 | 0.480 |
Why?
|
| Hematoma | 1 | 2015 | 108 | 0.470 |
Why?
|
| Urinary Catheters | 1 | 2014 | 6 | 0.470 |
Why?
|
| Aged | 47 | 2021 | 19165 | 0.470 |
Why?
|
| Urinary Catheterization | 1 | 2014 | 36 | 0.450 |
Why?
|
| Drainage | 1 | 2014 | 162 | 0.430 |
Why?
|
| Device Removal | 1 | 2014 | 168 | 0.410 |
Why?
|
| Urinary Diversion | 2 | 2010 | 42 | 0.400 |
Why?
|
| Curriculum | 2 | 2007 | 568 | 0.400 |
Why?
|
| Prospective Studies | 20 | 2014 | 4289 | 0.380 |
Why?
|
| Sural Nerve | 2 | 2008 | 19 | 0.380 |
Why?
|
| Neoplasm Staging | 16 | 2016 | 2018 | 0.380 |
Why?
|
| Laparoscopes | 2 | 2008 | 15 | 0.380 |
Why?
|
| Seminal Vesicles | 4 | 2021 | 39 | 0.370 |
Why?
|
| Humans | 84 | 2021 | 89356 | 0.360 |
Why?
|
| Treatment Outcome | 25 | 2020 | 8241 | 0.340 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2009 | 21 | 0.330 |
Why?
|
| Suture Techniques | 6 | 2010 | 140 | 0.320 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2009 | 103 | 0.310 |
Why?
|
| Follow-Up Studies | 14 | 2016 | 3666 | 0.310 |
Why?
|
| Urination Disorders | 4 | 2008 | 50 | 0.300 |
Why?
|
| Preoperative Care | 6 | 2013 | 396 | 0.300 |
Why?
|
| Retrospective Studies | 18 | 2020 | 9057 | 0.300 |
Why?
|
| Teaching Materials | 1 | 2007 | 14 | 0.300 |
Why?
|
| Learning | 2 | 2007 | 285 | 0.290 |
Why?
|
| Equipment Failure | 1 | 2007 | 121 | 0.290 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2008 | 401 | 0.260 |
Why?
|
| Educational Measurement | 1 | 2007 | 231 | 0.260 |
Why?
|
| Postoperative Care | 5 | 2014 | 231 | 0.250 |
Why?
|
| Biopsy, Needle | 6 | 2012 | 233 | 0.220 |
Why?
|
| Urethra | 2 | 2006 | 115 | 0.220 |
Why?
|
| Adult | 29 | 2016 | 26607 | 0.210 |
Why?
|
| Urologic Surgical Procedures | 2 | 2017 | 147 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2015 | 1365 | 0.210 |
Why?
|
| Postoperative Complications | 11 | 2011 | 2284 | 0.210 |
Why?
|
| Carcinoma, Giant Cell | 1 | 2002 | 2 | 0.210 |
Why?
|
| Multivariate Analysis | 8 | 2012 | 988 | 0.200 |
Why?
|
| Aged, 80 and over | 15 | 2011 | 6811 | 0.200 |
Why?
|
| Vaginal Neoplasms | 1 | 2002 | 84 | 0.200 |
Why?
|
| Disease-Free Survival | 6 | 2015 | 1214 | 0.200 |
Why?
|
| Appendix | 3 | 2011 | 31 | 0.190 |
Why?
|
| Cystadenoma | 1 | 2021 | 19 | 0.190 |
Why?
|
| Prostate-Specific Antigen | 8 | 2013 | 360 | 0.190 |
Why?
|
| Penile Erection | 1 | 2000 | 22 | 0.180 |
Why?
|
| Margins of Excision | 1 | 2020 | 39 | 0.180 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2000 | 30 | 0.180 |
Why?
|
| Clinical Competence | 3 | 2015 | 784 | 0.180 |
Why?
|
| Workload | 1 | 2020 | 129 | 0.170 |
Why?
|
| Urethral Diseases | 1 | 1999 | 15 | 0.170 |
Why?
|
| Ossification, Heterotopic | 1 | 1999 | 33 | 0.160 |
Why?
|
| Pelvic Bones | 1 | 1999 | 43 | 0.160 |
Why?
|
| Pelvis | 3 | 2015 | 96 | 0.160 |
Why?
|
| Phimosis | 1 | 1998 | 1 | 0.160 |
Why?
|
| Time Factors | 8 | 2014 | 5338 | 0.160 |
Why?
|
| Proportional Hazards Models | 4 | 2015 | 851 | 0.160 |
Why?
|
| Piperazines | 1 | 2000 | 283 | 0.160 |
Why?
|
| Biopsy | 9 | 2016 | 1184 | 0.160 |
Why?
|
| Surveys and Questionnaires | 8 | 2010 | 2624 | 0.160 |
Why?
|
| Nomograms | 2 | 2008 | 29 | 0.150 |
Why?
|
| Anastomosis, Surgical | 5 | 2011 | 273 | 0.150 |
Why?
|
| Spermine | 1 | 1998 | 24 | 0.150 |
Why?
|
| Urinary Bladder Neck Obstruction | 3 | 2008 | 21 | 0.150 |
Why?
|
| Fractures, Bone | 1 | 1999 | 128 | 0.150 |
Why?
|
| Lymphatic Metastasis | 3 | 2015 | 502 | 0.140 |
Why?
|
| Health Plan Implementation | 1 | 2017 | 56 | 0.140 |
Why?
|
| Urologic Diseases | 1 | 2017 | 44 | 0.140 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 106 | 0.140 |
Why?
|
| Urinary Bladder | 2 | 2010 | 246 | 0.140 |
Why?
|
| Overweight | 2 | 2008 | 119 | 0.140 |
Why?
|
| Child | 8 | 2017 | 7174 | 0.130 |
Why?
|
| Carcinoma, Ductal | 1 | 2015 | 18 | 0.130 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2015 | 12 | 0.130 |
Why?
|
| Learning Curve | 1 | 2015 | 19 | 0.130 |
Why?
|
| Ear Canal | 1 | 2015 | 16 | 0.130 |
Why?
|
| Probability | 4 | 2010 | 353 | 0.120 |
Why?
|
| General Surgery | 2 | 2008 | 236 | 0.120 |
Why?
|
| Operative Time | 1 | 2015 | 143 | 0.120 |
Why?
|
| Logistic Models | 5 | 2011 | 1213 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2015 | 216 | 0.120 |
Why?
|
| Neoplasm Grading | 4 | 2016 | 374 | 0.110 |
Why?
|
| Predictive Value of Tests | 7 | 2016 | 1723 | 0.110 |
Why?
|
| Age Factors | 6 | 2013 | 1870 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 576 | 0.110 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 2415 | 0.110 |
Why?
|
| Organ Size | 3 | 2010 | 371 | 0.100 |
Why?
|
| Brachytherapy | 2 | 2004 | 121 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 160 | 0.100 |
Why?
|
| Incidence | 5 | 2015 | 1595 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2015 | 427 | 0.100 |
Why?
|
| Ileum | 2 | 2010 | 160 | 0.100 |
Why?
|
| Chemoprevention | 1 | 2011 | 92 | 0.100 |
Why?
|
| Pain, Postoperative | 1 | 2014 | 252 | 0.100 |
Why?
|
| Kidney | 3 | 2009 | 1147 | 0.100 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 2011 | 14 | 0.090 |
Why?
|
| Ostomy | 1 | 2011 | 15 | 0.090 |
Why?
|
| Quality of Life | 3 | 2008 | 1668 | 0.090 |
Why?
|
| Apoptosis | 1 | 1998 | 1717 | 0.090 |
Why?
|
| Cystostomy | 1 | 2011 | 15 | 0.090 |
Why?
|
| Physicians | 2 | 2009 | 690 | 0.090 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2010 | 24 | 0.090 |
Why?
|
| Urodynamics | 3 | 2008 | 122 | 0.090 |
Why?
|
| Frozen Sections | 1 | 2010 | 49 | 0.090 |
Why?
|
| Risk Assessment | 5 | 2012 | 2303 | 0.090 |
Why?
|
| Immediate-Early Proteins | 1 | 2011 | 165 | 0.090 |
Why?
|
| Carcinoma | 1 | 2013 | 443 | 0.090 |
Why?
|
| Nephrectomy | 3 | 2007 | 295 | 0.090 |
Why?
|
| Wolffian Ducts | 1 | 2009 | 7 | 0.080 |
Why?
|
| Femoral Artery | 1 | 2009 | 83 | 0.080 |
Why?
|
| Anesthesia | 2 | 2009 | 170 | 0.080 |
Why?
|
| Intraoperative Complications | 2 | 2009 | 188 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2008 | 487 | 0.080 |
Why?
|
| Reoperation | 2 | 2009 | 599 | 0.080 |
Why?
|
| Radioimmunodetection | 1 | 2008 | 13 | 0.080 |
Why?
|
| Creatinine | 1 | 2009 | 293 | 0.080 |
Why?
|
| Neuromuscular Diseases | 1 | 2008 | 31 | 0.080 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2009 | 120 | 0.080 |
Why?
|
| Arthritis | 1 | 2008 | 47 | 0.080 |
Why?
|
| Aorta | 1 | 2009 | 288 | 0.080 |
Why?
|
| Perioperative Care | 1 | 2009 | 170 | 0.070 |
Why?
|
| Patient Selection | 1 | 2011 | 684 | 0.070 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2008 | 69 | 0.070 |
Why?
|
| Prognosis | 5 | 2016 | 3783 | 0.070 |
Why?
|
| Occupational Diseases | 1 | 2008 | 55 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2009 | 253 | 0.070 |
Why?
|
| Intestines | 1 | 2010 | 416 | 0.070 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2007 | 9 | 0.070 |
Why?
|
| Medical Illustration | 1 | 2007 | 16 | 0.070 |
Why?
|
| Contracture | 1 | 2006 | 18 | 0.070 |
Why?
|
| Urologic Neoplasms | 1 | 2007 | 84 | 0.070 |
Why?
|
| Urinary Bladder Diseases | 1 | 2006 | 41 | 0.070 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2009 | 227 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2010 | 548 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2008 | 236 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2020 | 2872 | 0.070 |
Why?
|
| Prostatic Hyperplasia | 2 | 1998 | 91 | 0.070 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2007 | 51 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 360 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 2007 | 122 | 0.060 |
Why?
|
| United States | 2 | 2015 | 6989 | 0.060 |
Why?
|
| Female | 11 | 2010 | 46202 | 0.060 |
Why?
|
| Regression Analysis | 3 | 2013 | 590 | 0.060 |
Why?
|
| Carcinoma, Medullary | 1 | 2004 | 10 | 0.060 |
Why?
|
| Risk Factors | 5 | 2011 | 5499 | 0.060 |
Why?
|
| Analysis of Variance | 3 | 2012 | 899 | 0.060 |
Why?
|
| Radiotherapy, Conformal | 1 | 2004 | 84 | 0.060 |
Why?
|
| Obesity | 2 | 2008 | 971 | 0.050 |
Why?
|
| Survival Rate | 3 | 2015 | 1901 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2004 | 179 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 1799 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2011 | 3731 | 0.050 |
Why?
|
| Kidney Neoplasms | 2 | 2007 | 638 | 0.050 |
Why?
|
| Genital Neoplasms, Male | 1 | 2021 | 11 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2016 | 1534 | 0.050 |
Why?
|
| Sildenafil Citrate | 1 | 2000 | 23 | 0.050 |
Why?
|
| Sulfones | 1 | 2000 | 45 | 0.050 |
Why?
|
| Purines | 1 | 2000 | 93 | 0.040 |
Why?
|
| Penis | 1 | 2000 | 60 | 0.040 |
Why?
|
| Hot Flashes | 1 | 2000 | 12 | 0.040 |
Why?
|
| Leuprolide | 1 | 2000 | 35 | 0.040 |
Why?
|
| Health Surveys | 1 | 2000 | 240 | 0.040 |
Why?
|
| Algorithms | 2 | 2007 | 1877 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 1998 | 1057 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2000 | 157 | 0.040 |
Why?
|
| Estrogens | 1 | 2000 | 201 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1998 | 65 | 0.040 |
Why?
|
| Neoplasm, Residual | 2 | 2012 | 181 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2004 | 1265 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 1431 | 0.040 |
Why?
|
| Risk | 2 | 2010 | 657 | 0.040 |
Why?
|
| Doxazosin | 1 | 1997 | 1 | 0.040 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1997 | 31 | 0.040 |
Why?
|
| Intraoperative Period | 2 | 2008 | 90 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 1998 | 397 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 416 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2017 | 83 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2010 | 780 | 0.030 |
Why?
|
| Plant Extracts | 1 | 1998 | 245 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 1998 | 206 | 0.030 |
Why?
|
| Mice, Nude | 1 | 1998 | 815 | 0.030 |
Why?
|
| Cell Survival | 1 | 1998 | 983 | 0.030 |
Why?
|
| Rats | 2 | 1998 | 4041 | 0.030 |
Why?
|
| Relative Biological Effectiveness | 2 | 2004 | 13 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1998 | 1942 | 0.030 |
Why?
|
| Adolescent | 3 | 2011 | 9263 | 0.030 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2013 | 15 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2008 | 354 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 856 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2013 | 102 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2013 | 251 | 0.030 |
Why?
|
| Chicago | 1 | 2016 | 1427 | 0.030 |
Why?
|
| Infant | 1 | 1998 | 3160 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2011 | 41 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2011 | 127 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 60 | 0.020 |
Why?
|
| Spinal Dysraphism | 1 | 2010 | 19 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 2011 | 123 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2010 | 84 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2004 | 1719 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 860 | 0.020 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2011 | 131 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2010 | 89 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 773 | 0.020 |
Why?
|
| Lymphocele | 1 | 2009 | 6 | 0.020 |
Why?
|
| Fasciotomy | 1 | 2009 | 17 | 0.020 |
Why?
|
| Vas Deferens | 1 | 2009 | 7 | 0.020 |
Why?
|
| Aortography | 1 | 2009 | 65 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2009 | 94 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 225 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2009 | 98 | 0.020 |
Why?
|
| Calibration | 1 | 2008 | 104 | 0.020 |
Why?
|
| Urography | 1 | 2008 | 45 | 0.020 |
Why?
|
| Ureter | 1 | 2009 | 93 | 0.020 |
Why?
|
| Cystoscopy | 1 | 2008 | 39 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 337 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2017 | 1045 | 0.020 |
Why?
|
| Mathematics | 1 | 2007 | 191 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2009 | 275 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1719 | 0.020 |
Why?
|
| Swine | 1 | 2009 | 582 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2009 | 996 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 1597 | 0.020 |
Why?
|
| Jamaica | 1 | 2007 | 5 | 0.020 |
Why?
|
| Mice | 2 | 1998 | 11761 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2008 | 302 | 0.020 |
Why?
|
| Equipment Design | 1 | 2008 | 417 | 0.020 |
Why?
|
| Animals | 3 | 2009 | 27369 | 0.020 |
Why?
|
| Demography | 1 | 2007 | 183 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 683 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2007 | 134 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2007 | 135 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 781 | 0.020 |
Why?
|
| Acute Disease | 1 | 2007 | 841 | 0.020 |
Why?
|
| Recurrence | 1 | 2008 | 1144 | 0.020 |
Why?
|
| Gene Library | 1 | 2004 | 133 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2004 | 188 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2004 | 299 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2003 | 470 | 0.010 |
Why?
|
| Administration, Cutaneous | 1 | 2000 | 60 | 0.010 |
Why?
|
| Disease Progression | 1 | 2004 | 1489 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2007 | 1549 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2661 | 0.010 |
Why?
|
| Neomycin | 1 | 1998 | 7 | 0.010 |
Why?
|
| Karyotyping | 1 | 1998 | 253 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1998 | 116 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1998 | 261 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 1998 | 618 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1998 | 1109 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1998 | 2362 | 0.000 |
Why?
|